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Predicting Which Children with Juvenile Idiopathic
Arthritis Will Not Attain Early Remission with
Conventional Treatment: Results from the
ReACCh-Out Cohort

Jaime Guzman, Andrew Henrey, Thomas Loughin, Roberta A. Berard, Natalie J. Shiff, Roman
Jurencak, Adam M. Huber, Kiem Oen, Kerstin Gerhold, Brian M. Feldman, Rosie Scuccimarri,
Kristin Houghton, Gaëlle Chédeville, Kimberly Morishita, Bianca Lang, Paul Dancey, Alan
M. Rosenberg, Julie Barsalou, Alessandra Bruns, Karen Watanabe Duffy, Susanne Benseler,
Ciaran M. Duffy, and Lori B. Tucker, and the ReACCh-Out Investigators
ABSTRACT. Objective. To estimate the probability of early remission with conventional treatment for each child
with juvenile idiopathic arthritis (JIA). Children with a low chance of remission may be candidates
for initial treatment with biologics or triple disease-modifying antirheumatic drugs (DMARD).
Methods. We used data from 1074 subjects in the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) cohort. The predicted outcome was clinically inactive disease for
≥ 6 months starting within 1 year of JIA diagnosis in patients who did not receive early biologic
agents or triple DMARD. Models were developed in 200 random splits of 75% of the cohort and
tested on the remaining 25% of subjects, calculating expected and observed frequencies of remission
and c-index values.
Results. Our best Cox logistic model combining 18 clinical variables a median of 2 days after
diagnosis had a c-index of 0.69 (95% CI 0.67–0.71), better than using JIA category alone (0.59, 95%
CI 0.56–0.63). Children in the lowest probability decile had a 20% chance of remission and 21%
attained remission; children in the highest decile had a 69% chance of remission and 73% attained
remission. Compared to 5% of subjects identified by JIA category alone, the model identified 14%
of subjects as low chance of remission (probability < 0.25), of whom 77% failed to attain remission.
Conclusion. Although the model did not meet our a priori performance threshold (c-index > 0.70),
it identified 3 times more subjects with low chance of remission than did JIA category alone, and it
may serve as a benchmark for assessing value added by future laboratory/imaging biomarkers.
(First Release January 15 2019; J Rheumatol 2019;46:628–35; doi:10.3899/jrheum.180456)
Key Indexing Terms:
JUVENILE IDIOPATHIC ARTHRITIS
RISK STRATIFICATION
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The prognosis of children with juvenile idiopathic arthritis
(JIA) has improved with modern treatments1. With stepwise
treatment escalation consistent with the 2011 Treatment
Recommendations of the American College of Rheumatology (ACR)2, herein referred to as conventional treatment,
45% of children attain inactive disease within 1 year of
diagnosis1. However, there is ongoing concern that children
who do not attain early remission may miss a hypothesized
window of opportunity to alter the disease trajectory, and
pilot studies of initial aggressive therapy with biologic agents
or triple disease-modifying antirheumatic drug (DMARD)
therapy have reported encouraging results3,4.
Most prognostic research on JIA has focused on identification of baseline predictors associated with a subsequent
outcome5,6, rather than on combining predictors into a
clinical prediction tool to estimate the likelihood of the
outcome for individual patients. Clinical prediction tools that
calculate individual risk, such as the Acute Physiologic
Assessment and Chronic Health Evaluation (APACHE)
score7 or the Framingham score8 have been available for
decades, but JIA prediction tools are a recent development.
In 2012, Bulatovic, et al reported a prediction model for
nonresponse to methotrexate [MTX; area under the
receiver-operating characteristic curve (AUC) 0.65]9. More
recently, van Dijkhuizen, et al reported a model to predict
MTX intolerance (c-index 0.667)10 and our group reported a
model to predict a severe JIA disease course (c-index 0.85)11.
Harrell’s c-index (equivalent to the AUC) is the most-quoted
performance measure when testing clinical prediction tools12.
A value of 0.5 corresponds to chance alone, while 1.0 means
perfect prediction. In the cardiovascular literature, values
> 0.70 are considered helpful prediction and values above
0.80 are considered excellent12.
We recently used data from the Research in Arthritis in
Canadian Children Emphasizing Outcomes (ReACCh-Out)
prospective inception cohort to develop a prediction model
for a severe JIA disease course with remarkable accuracy11.
We hypothesized that similar methods would lead to an
accurate model (c-index > 0.70) that could be used at
diagnosis to predict attainment of early clinical remission
with conventional treatment. Such a model would help target
initial treatment with biologics or triple DMARD to children
with a low chance of remission with conventional treatment,
and avoid such treatment in children who do not need it.
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MATERIALS AND METHODS

The ReACCh-Out study recruited children newly diagnosed with JIA from
2005 to 2010 at 16 Canadian Pediatric Rheumatology centers and followed
them for up to 5 years or until May 20121,13. The study received ethics
approval at each of the 16 centers with primary ethics approval at Montreal
Children’s Hospital, McGill University Health Centre (no. PED-04_065).
Study visits at 0, 6, 12, 18, 24, 36, 48, and 60 months after enrollment
included a full complement of physician-reported and patient-reported
measures1,13. During other visits to the clinic (interim visits), these variables
were reported: a physician’s global assessment (PGA) of disease activity,
active and restricted joint counts, enthesitis count, current medications and
erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) levels (if
clinically indicated). Information from all study visits and interim visits was
analyzed to determine attainment of remission as defined below.
Subjects were included if (1) they were enrolled within 90 days of
diagnosis, (2) they did not receive biologics or triple DMARD therapy within
6 months of diagnosis, and (3) the outcome was known. The outcome was
early remission while taking medication defined as 6 or more months of
clinically inactive disease14, starting within 1 year of diagnosis. Specifically,
there had to be 2 or more recorded study or interim visits in the database at
least 182 days apart with no evidence of active disease, including the
12-month study visit. None of the recorded visits during this time could
indicate any of the following: an active joint, enthesitis, a PGA of 1 or more
on a 10-cm visual analog scale (VAS), systemic JIA manifestations, active
uveitis, use of corticosteroid eye drops, morning stiffness > 15 min, ESR
> 20 mm/h or CRP > 5 mg/l. Attainment of early remission was adjudicated
by review of the data by 3 pediatric rheumatologists (JG, AMH, KO), who
were asked to exercise clinical judgment using all the available information
and to consider missing data; 155 subjects in whom the outcome could not
be adjudicated by the panel (mostly subjects who missed the 12-month visit),
were excluded. Subjects who discontinued treatment during the 182-day
period and remained inactive were still deemed to have attained remission
on medication. The date of remission was the date of the first recorded visit
with no evidence of active disease.
An acceptable prediction model was defined a priori as having a c-index
> 0.7012. If the initial approach failed to produce this, our study protocol
called for time-to-event analysis (Cox regression) of all subjects recruited
within 90 days of diagnosis who had followup information.

Candidate predictor variables. Eighty-seven variables assessed at enrollment
were considered for inclusion in prediction models. They were selected
because there was (1) a reported association with remission5,6, (2) an association with early inactive disease in our previous study13, or (3) a plausible
association with remission in the authors’ opinion.
Among these 87 variables, 51 were associated with early remission with
a p value < 0.2 in univariable screening with logistic regression. The correlation among pairs of variables was assessed using the Pearson correlation
coefficient and correlated variables that were duplicate measures of the same
construct, or subdomains within a measure were excluded (n = 17). Fifteen
variables with a p > 0.2 were included because of strong support in previous
studies and because most clinicians would like to ensure they were
considered. Thus, a total of 49 variables were included in modeling. These
were grouped by pediatric rheumatologists (RAB, JG, AMH, KO, NJS,
LBT) as easy, moderate, or hard to ascertain in routine pediatric rheumatology practice. In general, variables such as which joints were involved,
routine laboratory results, and PGA were considered easy, variables derived
from the Childhood Health Assessment Questionnaire (CHAQ) were
considered moderate, and variables derived from the Juvenile Arthritis
Quality of Life Questionnaire were considered hard. Supplementary Tables
1–5 (available with the online version of this article) list all 87 variables and
their disposition.
Development and testing of prediction models. Prediction models were
developed using the methods reported by Guzman, et al11, with the modifications described here. All modeling was done with R software
(www.r-project.org) and descriptive statistics were calculated with STATA
12 (StataCorp LLC).
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Missing data on predictors were imputed by multiple imputation using
the mice package in R15. With about 11% missing data, we opted for 20
imputed datasets as recommended by Bodner16.
For each imputed dataset, we created 10 random training (75%) and test
(25%) splits. Models were developed in the training set, and their
performance assessed in the test set. This allowed an honest assessment of
models, preventing any overfitted models from giving an inflated impression
of model performance. Models were fit using easy variables only, easy and
moderate variables, or all the variables. In each of the training sets, we fitted
a logistic model, a classification tree, neural networks, and several types of
random forest (with various tuning parameters). Model results were calculated in the test sets averaging the 10 splits of the data in the 20 imputed
datasets.
Our main metric to assess model performance was the c-index, supplemented by the logarithmic scoring rule and a method based on a chi-square
goodness of fit test11. We also calculated the proportion of subjects identified
as having a low chance of remission (probability < 0.25) and explored
whether subjects at risk of a severe disease course using our previous
model11 had a low chance of early remission. While the cutoff for a low
chance of remission is arbitrary (people have different opinions of what is
too low), we believe that a < 1-in-4 chance of remission with conventional
treatment would prompt most clinicians and families to consider aggressive
initial treatment.
Because the initial models had a c-index < 0.70, we proceeded to
time-to-event analysis in an extended dataset of 1074 subjects. A test set of
184 randomly selected subjects with known remission status was reserved
for testing models only. Data from the remaining subjects were used
to develop the Cox regression models. The time-to-remission and
time-to-inactive disease Cox models create a prediction of how long it would
take a patient to attain the outcome after diagnosis. We used that prediction
as an additional covariate in the logistic model for probability of remission
at 1 year. Time to event was the elapsed time from the date of diagnosis to
the date of the first visit with no evidence of active disease. In essence, these
models summarize the same patient baseline data in a different way for the
model to consider. In our final model, it was found to offer a statistically
significant improvement in performance. The advantage is that Cox models
use information from 158 additional subjects and that time to attainment of
an outcome may be more informative than a dichotomous yes/no. Because
competing models are tested in the same set of subjects, we used a paired
testing procedure to estimate improvements in c-index associated with Cox
logistic models.
We conducted sensitivity analyses in patient subgroups to assess whether
the heterogeneity among patients with JIA interfered with our ability to find
a model with greater prediction accuracy. We repeated analyses for patients
with oligoarthritis and rheumatoid factor (RF)–negative polyarthritis together,
and for children presenting with 4 or fewer joints versus 5 or more joints
involved, after excluding patients with active sacroiliitis or systemic JIA (i.e.,
the first 2 treatment groups in the ACR treatment recommendations)2.

RESULTS
Of 1497 subjects with JIA recruited into the ReACCh-Out
cohort, 5 were excluded owing to unknown JIA category, 353
for enrollment > 90 days from diagnosis, 65 because they
attended only the enrollment visit, 155 because the outcome
could not be adjudicated, and 3 because they received
biologic agents within 6 months of diagnosis (2 received
anakinra, 1 infliximab; no subject received early triple
DMARD therapy). This left 916 subjects in our binary
analyses. Subjects were enrolled a median of 2 days after
diagnosis, and two-thirds were female (Table 1). Patients with
oligoarthritis, RF-negative polyarthritis, or enthesitis-related
arthritis formed 74% of the cohort. The median PGA was 2.9
630

and the median active joint count was 2; 405 subjects (44.2%)
attained early remission. Many variables were associated
with early remission in univariable analysis (Table 1).
There were 1074 subjects eligible for Cox regression.
Characteristics of excluded subjects and subjects included
only in Cox analyses, details of the multiple imputation
method, and the univariable associations with early remission
for all 87 candidate predictors are reported in Supplementary
Tables 1–5 (available with the online version of this article).
Prediction models. In our binary analyses of 916 patients, the
best-performing model was a random forest using 49
variables (c-index 0.65, 95% CI 0.62–0.68), a modest
improvement compared to using JIA category alone (0.59,
95% CI 0.56–0.63). Using high risk of a severe disease
course calculated by our previous model11 as indicative of a
low probability of remission, the c-index was also 0.59 (95%
CI 0.56–0.61).
Because binary models did not attain the target c-index of
> 0.70, we proceeded to Cox analyses of 1074 subjects. This
resulted in a best-performing Cox logistic model with a
c-index of 0.69 (95% CI 0.67-0.71). The Cox logistic model
improved the c-index by 0.04 (95% CI 0.02–0.06) relative to
a simple logistic model and by 0.09 (95% CI 0.07–0.12)
relative to using JIA category alone.
Table 2 reports the expected and observed frequencies of
early remission with conventional treatment for subjects in
each decile of risk for 3 models (Cox logistic, binary random
forest, JIA category alone); these were calculated by ordering
subjects in the test set from lowest to highest probability of
remission as assigned by each model and dividing them into
10 groups with equal numbers of subjects (deciles).
The final Cox logistic model used 18 variables including
PGA, JIA category, the pattern of joint involvement, and
other routine measures that were assessed a median of 2 days
after diagnosis. Also included were the patient/parent global
assessment, pain in last week, French ethnicity, and joint
swelling reported by parents (Table 3). Using this final
model, a child’s probability of early remission while taking
medications with conventional treatment, expressed as a
percentage, is given by 100 * [eA/(1 + eA)], where eA is the
natural antilogarithm of A and A is calculated as the
following: A = –0.23 + 0.91 (Cox predictor for time to
remission on medications) + 0.12 (Cox predictor for time to
inactive disease). The probability of early remission with
conventional treatment for any child with JIA can be obtained
using the online calculator available at andrew-j-henrey.
shinyapps.io/JIA_Remission_Calc.
If instead of considering the probability of remission, one
wished to use model results as a dichotomous diagnostic test
for non-remission, the cutoff of < 0.5 probability of remission
results in a sensitivity of 0.71 and specificity of 0.57, while
the cutoff of < 0.25 results in a sensitivity of 0.20 and specificity of 0.76. If one accepts that a probability of remission
of < 0.25 with conventional treatment would justify
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Table 1. Baseline patient characteristics and univariable associations with attainment of early remission while taking medication.
Characteristics

All, n = 916

Female sex, n = 898**
593 (66)
Age at onset, yrs, n = 896
8.2 (3.0, 11.9)
Weeks from onset to diagnosis, n = 883
18.6 (9.3, 38.7)
Weeks from diagnosis to enrollment, n = 916
0.2 (0, 5.7)
Ethnicity, n = 870
Any French
272 (31)
Any British
459 (53)
No French or British
251 (29)
JIA category
Oligoarthritis
365 (40)
RF– polyarthritis
194 (21)
Enthesitis-related
118 (13)
Systemic
58 (6)
Psoriatic
48 (5)
RF+ polyarthritis
40 (4)
Undifferentiated
93 (10)
Initial treatment***, n = 907
NSAID
845 (93)
Joint injections
218 (24)
DMARD
241 (27)
Corticosteroids
143 (16)
Treatment in first year, n = 914
NSAID
845 (93)
Joint injections
296 (33)
DMARD
412 (45)
Corticosteroids
152 (17)
Biologics
37 (4)
Physician report
PGA, 0–10, n = 906
2.9 (1.4, 5.1)
Active joint count, 0–71, n = 899
2 (1, 7)
Patient/parent report
CHAQ Disability Index, 0–3, n = 730
0.5 (0.1, 1.0)
JAQQ, 1–7, n = 757
2.8 (1.9, 4.0)
Parent global assessment of well-being,
0–10, n = 790
1.9 (0.5, 4.7)
Quality of My Life scale, 0–10, n = 765
7.7 (5.2, 9.2)
Pain intensity in last week, 0–10, n = 790
3.0 (0.9, 5.8)
Presence of morning stiffness, n = 832
412 (50)
Joint swelling observed by parents, n = 914
774 (85)
Pattern of joint involvement, n = 899
Symmetric
440 (49)
Temporal mandibular
50 (6)
Wrist
261 (29)
Finger
301 (33)
Upper limb
411 (46)
Ankle
335 (37)
Subtalar
127 (14)
Presence of enthesitis, n = 907
81 (9)
No. enthesitis sites, n = 81
2 (1,5)
Laboratory tests
RF-positive at least once, n = 815
67 (8)
CRP, mg/l, n = 746
3 (0.3, 12.1)
ESR, mm/h, n = 837
18 (5, 34)
ANA-positive, n = 845
427 (51)
B27-positive, n = 444
97 (22)

Attained Early
Remission,
n = 405, 44%

Did Not Attain
Early Remission,
n = 511, 56%

Univariable OR
for Early Remission
(95% CI) *

137 (50)
186 (41)
106 (42)

135 (50)
273 (59)
145 (58)

1.37 (0.94–2.00)
0.75 (0.53–1.04)
0.89 (0.66–1.20)

0.091
0.078
0.445
< 0.001

1.11 (0.57–2.17)
0.88 (0.79–0.99)
0.65 (0.45–0.95)
0.61 (0.37–1.01)

0.756
0.031
0.022
0.048

0.84 (0.79–0.91)
0.96 (0.94–0.98)

< 0.001
< 0.001

257 (43)
7.8 (2.8, 11.4)
15.9 (7.7, 30.9)
1 (0, 5.9)

197 (54)
74 (38)
46 (39)
27 (47)
25 (52)
6 (15)
30 (32)

375 (44)
108 (49)
92 (38)
48 (34)

362 (43)
114 (39)
139 (34)
50 (33)
10 (27)

2.4 (1.1, 4.2)
2 (1, 4)

0.4 (0, 0.7)
2.4 (1.8, 3.6)

336 (57)
8.6 (3.1, 12.6)
21.8 (10.7, 48)
0 (0, 5.6)

168 (46)
120 (62)
72 (61)
31 (53)
23 (48)
34 (85)
63 (68)

470 (56)
110 (51)
149 (62)
95 (66)

479 (57)
182 (61)
273 (66)
102 (67)
27 (73)

3.5 (1.9, 5.7)
3 (1, 9)

0.6 (0.1, 1.1)
3.1 (2.1, 4.3)

1.5 (0.3, 4.0)
8.1 (5.8, 9.5)
2.1 (0.5, 5)
163 (40)
348 (45)

2.3 (0.7, 4.9)
7.5 (5.0, 8.9)
3.9 (1.2, 6.1)
249 (60)
426 (55)

13 (19)
2.6 (0.3, 10.8)
16 (8, 33)
187 (44)
48 (49)

54 (81)
3.1 (0.4, 14.1)
18 (4, 35)
240 (56)
49 (51)

157 (36)
14 (28)
93 (36)
97 (32)
148 (36)
134 (40)
41 (32)
27 (33)
1 (1, 5)

283 (64)
36 (72)
168 (64)
204 (68)
263 (64)
201 (60)
86 (68)
54 (67)
2 (1, 7)

0.80 (0.57–1.14)
0.97 (0.94–1.01)
1.0 (0.99–1.0)
1.07 (0.89–1.29)

1.22 (0.97–1.54)
0.55 (0.39–0.79)
0.67 (0.43–0.99)
1.04 (0.58–1.88)
1.29 (0.68–2.46)
0.24 (0.10–0.59)
0.49 (0.30–0.81)

0.60 (0.46–0.79)
0.75 (0.66–0.85)

p
0.202
0.097
0.016
0.453

< 0.001
< 0.001

0.91 (0.85–0.97)
1.11 (1.04–1.18)
0.87 (0.82–0.93)
0.65 (0.45–0.94)
1.25 (0.77–2.03)

0.002
0.002
< 0.001
0.018
0.357

0.31 (0.14–0.68)
0.99 (0.99–1.00)
1.00 (0.99–1.00)
0.97 (0.58–1.60)
1.15 (0.53–2.49)

0.003
0.010
0.342
0.890
0.722

0.48 (0.34–0.66)
0.55 (0.32–0.94)
0.59 (0.41–0.84)
0.45 (0.32–0.64)
0.51 (0.37–0.71)
0.73 (0.53–1.02)
0.56 (0.33–0.96)
0.64 (0.37–1.09)
0.87 (0.79–0.96)

< 0.001
0.024
0.003
< 0.001
< 0.001
0.063
0.032
0.094
0.004

Values are n (%) for categorical variables, and median (25th, 75th centiles) for continuous and ordinal variables. Onset means the date of the first disease
symptom. * Univariable OR calculated with logistic regression after multiple imputation of missing data. ** No. after the variable name is the no. of subjects
with data for that variable. *** Treatment received before study enrollment or prescribed at enrollment. Three subjects who received biologic agents within 6
months of diagnosis were excluded from the study. Joint injections occurring up to 1 month after enrollment were counted as “prescribed at enrollment.”
Treatment received in the first year is reported for descriptive purposes; it was not assessed as predictor of remission. JIA: juvenile idiopathic arthritis; RF:
rheumatoid factor; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs; PGA: physician’s global assessment of
disease activity; CHAQ: Childhood Health Assessment Questionnaire; JAQQ: Juvenile Arthritis Quality of Life Questionnaire; CRP: C-reactive protein; ESR:
erythrocyte sedimentation rate; ANA: antinuclear antibody.
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Table 2. Percentage of subjects with predicted and observed early remission in the test set by decile of risk and model performance statistics.
Decile

1 (lowest chance of remission)
2
3
4
5
6
7
8
9
10 (highest chance of remission)
C-index (95% CI)
Maximum likelihood
Pearson statistic
< 25% chance of remission, %

Cox Logistic Model, n = 184
Predicted/observed
20/21*
25/28
31/33
36/36
43/39
48/44
53/49
59/58
64/65
69/73
0.69 (0.67–0.71)
–117.6
11.16
14

Random Forest Binary Model, n = 184
Predicted/observed
22/25
30/34
35/35
39/37
43/41
47/44
51/45
55/52
62/62
74/72
0.65 (0.62–0.68)
–120.0
10.24
7

JIA Category Alone, n = 184
Predicted/observed
25/25
35/42
37/38
39/36
42/40
50/53
54/57
55/53
55/56
55/48
0.59 (0.56–0.63)
–123.8
11.10
5

* Values are the percentage of children in that decile predicted to attain early remission by the model compared to the actual observed frequency of attained
remission. Numbers are the mean of 10 runs per each of 20 imputed datasets in the test set of subjects not included in model development. Because the frequency
of early remission was 44% in the whole cohort, a perfect prediction model would have 0% predicted/observed remission in deciles 1–5, about 50% in decile
6, and 100% in deciles 7–10. Higher values of c-index and maximum likelihood indicate better performance. Lower values of Pearson statistic indicate better
performance. JIA: juvenile idiopathic arthritis.

Table 3. Baseline variables included in the final Cox logistic prediction model.
Variable

PGA
Weeks from onset to diagnosis**
RF+ polyarthritis
RF positive at least once
Systemic arthritis
Wrist involvement***
Subtalar joint involvement
Symmetric joint involvement
Upper limb involvement
Lower limb involvement
Pain intensity in last week
Parent global assessment of well-being***
Presence of enthesitis
No. enthesitis sites
B27-positive
ANA-positive
Any French ethnicity
Joint swelling reported by parents

Adjusted HR for Time to
Remission While Taking
Medications* (95% CI)

p

0.933 (0.888–0.981)
0.997 (0.995–0.999)
0.383 (0.150–0.978)
–
0.550 (0.308–0.983)
–
0.670 (0.482–0.931)
0.777 (0.616–0.979)
–
–
0.927 (0.874–0.983)
–
–
0.960 (0.921–1.001)
0.699 (0.492–0.994)
0.793 (0.654–0.961)
1.291 (1.069–1.559)
1.338 (1.006–1.767)

0.005
0.003
0.041
–
0.039
–
0.015
0.029
–
–
0.010
–
–
0.050
0.042
0.016
0.007
0.041

Adjusted HR for Time
to Inactive Disease*
(95% CI)
0.955 (0.917–0.994)
0.998 (0.996–0.999)
–
0.630 (0.419–0.948)
0.489 (0.304–0.787)
1.328 (1.025–1.720)
0.770 (0.600–0.990)
–
0.642 (0.480–0.859)
0.696 (0.564–0.860)
0.926 (0.883–0.970)
1.054 (1.013–1.098)
0.748 (0.563–0.994)
–
0.731 (0.561–0.952)
0.858 (0.734–1.002)
1.127 (1.005–1.378)
1.306 (1.047–1.629)

p

0.021
< 0.001
–
0.024
0.003
0.028
0.038
–
0.002
0.001
0.001
0.009
0.041
–
0.018
0.048
0.039
0.016

* Values are HR calculated from a multivariable Cox regression model that includes all the listed variables simultaneously; the dash means the association was
not statistically significant (p > 0.05). ** Onset means the date of the first JIA symptom. *** Wrist involvement and a higher parent global assessment are
associated with decreased probability of early remission in univariable logistic regression, but when considered together with all other variables incorporated
in this multivariable Cox model, they increase the probability of remission calculated by the model. PGA: physician’s global assessment of disease activity;
RF: rheumatoid factor; ANA: antinuclear antibody; JIA: juvenile idiopathic arthritis.

aggressive initial treatment, JIA category alone identifies 5%
of subjects as candidates for aggressive treatment (primarily
subjects with RF-positive polyarthritis) and 70% of those
subjects did not attain early remission with conventional
treatment. Our top Cox logistic model identifies 14% of
subjects as candidates for aggressive treatment, and 77% of
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them did not attain early remission. For reference, our previously published model11 identifies 13% of subjects in the
current sample as high risk for a severe disease course and
77% of them did not attain early remission. The overlap of
subjects identified by the 2 models is 39%.
Our sensitivity analyses in JIA patient subgroups did not

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2019. All rights reserved.

The Journal of Rheumatology 2019; 46:6; doi:10.3899/jrheum.180456

Downloaded on August 8, 2022 from www.jrheum.org

improve prediction accuracy because they had c-index values
of 0.64 to 0.68 (Supplementary Tables 1–5, available with
the online version of this article).

DISCUSSION
We used clinical and routine laboratory data from a large
prospective inception cohort of children with JIA to develop
a model to predict attainment of early disease remission with
conventional treatment. With a c-index of 0.69, our best
performing model was better than using JIA category alone
but fell short of the threshold of > 0.70 recommended for
clinical prediction tools12. However, this model identified 3
times as many children with a low chance of remission
compared to using the JIA category alone (14% vs 5%). This
may well be the limit of prediction accuracy attainable with
routine clinical and laboratory variables, and novel
biomarkers may be required to improve prediction accuracy.
Our model can serve as a benchmark to evaluate the value
added by potential JIA laboratory/imaging biomarkers in
future research.
Our model includes 2 patient-reported outcomes, the
parent’s/patient’s global assessment of well-being and pain
severity in the last week. Thus, in addition to their value as
outcomes, these 2 components of the CHAQ17 help predict
response to conventional treatment, even after accounting for
clinical and laboratory variables.
The model includes 2 unexpected variables that increase
the likelihood of early remission: French ethnicity and joint
swelling observed by parents. This may mean that JIA is less
severe in children with French ethnicity, but it could also be
a reflection of differences in treatment approach or physicians’ assessment of attainment of remission in French
Canada relative to English Canada. Easily visible swollen
joints such as knees may be more frequently involved in
children with mild disease (e.g., oligoarthritis) or prompt
earlier referral and treatment. A longer time from onset to
diagnosis decreased the chances of early remission.
The interaction between treatment intensity and
attainment of early remission merits careful consideration. In
our study, patients who did not attain remission were more
often prescribed early DMARD and systemic corticosteroids.
This suggests that physicians identified their disease as
severe, but the increased treatment was not uniformly
successful in attaining early remission. Incorporating initial
use of DMARD or corticosteroids as predictors in our current
study did not improve the accuracy of the models. It could
be argued that our excluding patients who received early
aggressive treatment left only subjects with relatively benign
disease in the study. The advantage of using the ReACCh-Out
dataset in our study is that patients were diagnosed in
2005–2010, a time when early aggressive treatment was
infrequent in Canada. There were only 3 subjects excluded
because of use of a biologic agent within 6 months of
diagnosis and no patient was excluded because of early triple

DMARD therapy. Because this represents < 0.5% of eligible
subjects, we believe their exclusion did not significantly bias
the population toward benign disease. It is likely that
including response to treatment at 3 or 6 months after
diagnosis will improve prediction of remission, but we chose
not to include this information in our present study because
our goal was to predict attainment of early remission at
diagnosis to make the most of the hypothesized window of
opportunity to change disease trajectory.
JIA is a heterogeneous group of disorders and current JIA
categories may not be the best way to categorize subjects,
thus we conducted sensitivity analyses in alternative subject
groupings, excluding JIA category as a predictor. These sensitivity analyses found no increased prediction accuracy
relative to our main model.
The strength of our study is that we used prospectively
collected data from a large cohort of patients enrolled shortly
after diagnosis and analyzed candidate predictors usually
available in routine clinical settings, always testing model
accuracy in subjects not included in model development to
prevent overfitting. However, our study has some limitations.
First, it is conceivable that other information not collected in
the ReACCh-Out cohort may improve prediction. Second,
missing data are unavoidable in large cohorts in regular
practice; we have addressed missing data with multiple
imputation, and by having a panel of 3 pediatric rheumatologists adjudicate remission. Third, our definition of remission
while taking medications may have missed some subjects
who had inactive disease for 6 months shortly after diagnosis,
if they had active disease at the 12-month visit. We felt that
such short-lived episodes of disease control were not very
meaningful. Fourth, our findings may not be generalizable to
other countries (e.g., French ethnicity may only be relevant
in some countries). Fifth, the patient/parent global and pain
severity assessments included in the model were completed
by the patient or a parent (for younger children) and this mix
of patient and parent-reported scores may be problematic;
reassuringly, although parent reports may over- or underrepresent the child’s pain, on average the difference is only 0.04
cm in a 10-cm VAS18. The fact that some patients/parents
answered questionnaires in French should not have interfered
with our outcome assessment, because pain scores and
parent’s global assessments did not form part of our definition
of inactive disease. Differences between French and English
may have increased variability in assessment of those
variables as predictors in the models; however, the linguistic
equivalence of the questions was judged adequate by
bilingual speakers, and the French version of the CHAQ has
been validated by Pouchot, et al19. Last, conventional
treatment in our study was consistent with the 2011 ACR
treatment recommendations2, but treatment evolves over time
and treatment recommendations are updated.
Because our model did not reach conventional thresholds
for accuracy of clinical prediction tools and it is unclear how
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it will perform in other settings, routine adoption in clinical
practice is not advisable at this time. An alternative is to use
our model to predict a severe disease course instead11, recognizing it does not predict early remission directly. The
argument in its favor is that that model is very accurate and
children at high risk of a severe disease course may benefit
from more aggressive initial treatment even if their short-term
response to conventional treatment is less predictable. It will
be important to assess how both prediction models fare when
tested in other inception cohorts.
Some physicians may find it helpful to use the current
model’s predictions or the univariable associations reported
in Table 1 in selected cases to augment their clinical
judgment. Because the likelihood of remission estimated by
the model closely paralleled the observed frequency of
remission, the model estimates could be shared with families
in Canada as a starting point for discussing the choice of
initial treatment.
By combining clinical and laboratory findings at
diagnosis, we developed a model that estimates the probability of early remission with conventional treatment for each
child with JIA and helps identify children with a low chance
of remission. The model was superior to using JIA category
alone but fell short of accepted thresholds for performance
of clinical prediction tools. Importantly, this constitutes proof
of principle that systematic study of existing JIA cohorts can
generate new information to assist with treatment decision
making in individual patients. Further research is critical to
improve the accuracy of predictions and may include the use
of novel laboratory and imaging (ultrasound, magnetic
resonance imaging) biomarkers and advanced modeling
techniques; our results can be used as a benchmark to
evaluate the value added by those novel approaches.
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